AtriCure, Inc. $ATRC Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC reduced its stake in AtriCure, Inc. (NASDAQ:ATRC) by 74.0% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 9,627 shares of the medical device company’s stock after selling 27,454 shares during the period. SG Americas Securities LLC’s holdings in AtriCure were worth $275,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of ATRC. Diversified Trust Co increased its position in shares of AtriCure by 7.1% during the first quarter. Diversified Trust Co now owns 40,090 shares of the medical device company’s stock valued at $1,144,000 after acquiring an additional 2,654 shares during the last quarter. Hsbc Holdings PLC lifted its holdings in shares of AtriCure by 13.3% in the 4th quarter. Hsbc Holdings PLC now owns 17,224 shares of the medical device company’s stock worth $686,000 after acquiring an additional 2,028 shares during the last quarter. Rockefeller Capital Management L.P. lifted its holdings in shares of AtriCure by 43.4% in the 4th quarter. Rockefeller Capital Management L.P. now owns 3,983 shares of the medical device company’s stock worth $158,000 after acquiring an additional 1,205 shares during the last quarter. Invesco Ltd. boosted its position in shares of AtriCure by 7.9% during the 4th quarter. Invesco Ltd. now owns 74,435 shares of the medical device company’s stock worth $2,945,000 after purchasing an additional 5,462 shares during the period. Finally, Mackenzie Financial Corp boosted its position in shares of AtriCure by 5.3% during the 4th quarter. Mackenzie Financial Corp now owns 13,597 shares of the medical device company’s stock worth $545,000 after purchasing an additional 683 shares during the period. Institutional investors and hedge funds own 99.11% of the company’s stock.

Insider Activity at AtriCure

In related news, Director Karen Prange sold 3,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 20th. The shares were sold at an average price of $28.65, for a total value of $85,950.00. Following the sale, the director owned 26,373 shares of the company’s stock, valued at $755,586.45. This trade represents a 10.21% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 4.00% of the company’s stock.

AtriCure Trading Down 0.8%

ATRC opened at $34.28 on Friday. The business has a fifty day moving average price of $28.66 and a 200 day moving average price of $31.82. The company has a debt-to-equity ratio of 0.15, a current ratio of 4.29 and a quick ratio of 3.18. AtriCure, Inc. has a 12 month low of $25.36 and a 12 month high of $43.18. The stock has a market capitalization of $1.74 billion, a price-to-earnings ratio of -342.80 and a beta of 1.24.

Analyst Upgrades and Downgrades

ATRC has been the topic of a number of research analyst reports. Wall Street Zen lowered AtriCure from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 2nd. Weiss Ratings lowered AtriCure from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, May 4th. Freedom Capital raised AtriCure to a “strong-buy” rating in a research note on Wednesday, April 1st. Zacks Research lowered AtriCure from a “strong-buy” rating to a “hold” rating in a research note on Thursday, June 4th. Finally, Canaccord Genuity Group lifted their target price on AtriCure from $53.00 to $55.00 and gave the company a “buy” rating in a research report on Wednesday, May 6th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $48.71.

AtriCure Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.